Who are BAT2206's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nivolumab + Relatlimab, Nivolumab-relatlimab FDC, Cadonilimab (AK104), Durvalumab +Tremelimumab, SHR-A1811 for Injection, MEDI4736 + Tremelimumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bat2206.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

BAT2206 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BAT2206 (BAT2206) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific antibody; dual checkpoint inhibitor. Area: Oncology.

phase 3 Bispecific antibody; dual checkpoint inhibitor Likely PD-1 and LAG-3 (or similar dual checkpoint targets) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

BAT2206 (BAT2206) — Bio-Thera Solutions. BAT2206 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T-cell responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BAT2206 TARGET	BAT2206	Bio-Thera Solutions	phase 3	Bispecific antibody; dual checkpoint inhibitor	Likely PD-1 and LAG-3 (or similar dual checkpoint targets)
Nivolumab + Relatlimab	Nivolumab + Relatlimab	H. Lee Moffitt Cancer Center and Research Institute	marketed	Dual checkpoint inhibitor (PD-1 and LAG-3 inhibitor combination)	PD-1 and LAG-3
Nivolumab-relatlimab FDC	Nivolumab-relatlimab FDC	Bristol-Myers Squibb	phase 3	Dual checkpoint inhibitor (PD-1/LAG-3)	PD-1 and LAG-3
Cadonilimab (AK104)	Cadonilimab (AK104)	Guangxi Medical University	phase 3	Bispecific monoclonal antibody; dual checkpoint inhibitor	PD-L1 and TIM-3
Durvalumab +Tremelimumab	Durvalumab +Tremelimumab	AstraZeneca	phase 3	Dual checkpoint inhibitor combination (PD-L1 inhibitor + CTLA-4 inhibitor)	PD-L1 and CTLA-4
SHR-A1811 for Injection	SHR-A1811 for Injection	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	phase 3	Bispecific monoclonal antibody; dual checkpoint inhibitor
MEDI4736 + Tremelimumab	MEDI4736 + Tremelimumab	AstraZeneca	phase 3	Dual checkpoint inhibitor (PD-L1 inhibitor + CTLA-4 inhibitor)	PD-L1 and CTLA-4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific antibody; dual checkpoint inhibitor class)

Bio-Thera Solutions · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BAT2206 — Competitive Intelligence Brief. https://druglandscape.com/ci/bat2206. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing